Recent 8-K filings for NTRB

• April 7, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband selects brand name for abuse-deterrent fentanyl patch; will submit to FDA

  Selected commercial worldwide brand name candidate for lead product, a fentanyl transdermal system with abuse-deterrent technology.

• February 13, 2026, 6:59 PM ET other material materiality 0.70 negative item 7.01item 9.01

  Nutriband terminates sale of Pocono Pharmaceuticals to Earth Vision Bio due to buyer default

  Board approved immediate termination of Pocono Pharmaceuticals sale to Earth Vision Bio Inc.

• December 30, 2025, 6:59 PM ET M&A materiality 0.75 positive item 7.01item 9.01

  Nutriband sells 90% stake in Pocono Pharma for $5M to EarthVision Bio; retains 10%

  Agreement to sell 90% interest in subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.

• October 28, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 7.01item 9.01

  Nutriband receives FDA feedback on AVERSA FENTANYL CMC plans; regulatory pathway confirmed as 505(b)(2)

  FDA meeting held September 18, 2025; final minutes received; feedback on CMC, registration batch, and stability plans.

• February 13, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Nutriband formalizes exclusive Aversa Fentanyl partnership with Kindeva; potential $80-200M US sales

  Signed addendum formalizing exclusive development partnership for Aversa Fentanyl with Kindeva Drug Delivery.

• February 12, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband receives USPTO Notice of Allowance for Aversa abuse deterrent patent

  Notice of Allowance received Feb 3, 2025 for patent app 18/369,241 covering Aversa abuse deterrent transdermal systems.

• September 18, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband announces $1 million share repurchase program; reaffirms AVERSA Fentanyl NDA timeline

  Share buyback program authorizes repurchase of up to $1,000,000 of common stock.

• April 23, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01 ◈ Material Agreements

  Nutriband raises $8.4M in Regulation S equity offering of units with warrants

  Offered 2.1M units at $4.00 each, each unit comprising one common share and warrant to buy two shares.

• January 11, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch

  Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.

• July 14, 2023, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 9.01 ◈ Material Agreements

  Nutriband replaces $2M credit line with $5M facility at 7% for AVERSA Fentanyl

  Secured $5M credit line at 7% interest, maturing July 13, 2026, replacing prior $2M facility.

• March 29, 2023, 7:59 PM ET debt materiality 0.65 positive item 7.01item 9.01

  Nutriband secures $2M credit line for AVERSA Fentanyl commercialization

  Three-year $2,000,000 credit line at 7% interest, non-convertible to common stock.

• July 26, 2022, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband cancels 1.2M shares (~15% of outstanding) after final court judgment rescinding 2017 acquisition

  Final Judgment permits cancellation of 1,200,000 shares issued in 2017 for rescinded Advanced Health Brands deal.

• July 15, 2022, 7:59 PM ET litigation materiality 0.70 positive item 7.01item 9.01

  Nutriband wins court verdict to rescind 2017 acquisition and recover 1.2M shares (~15% of outstanding)

  Circuit Court in Orange County, Florida ruled in favor of Nutriband on all issues, rescinding the Advanced Health Brands acquisition.

• January 31, 2022, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband receives US patent for AVERSA abuse deterrent transdermal technology

  USPTO issued patent for 'Abuse and Misuse Deterrent Transdermal System' covering AVERSA platform.

• January 27, 2022, 6:59 PM ET other material materiality 0.70 positive item 5.02item 5.03item 5.07item 7.01item 9.01 ◈ executive_change ×2

  Nutriband expands AVERSA abuse-deterrent pipeline to include buprenorphine and methylphenidate

  Adds AVERSA buprenorphine and AVERSA methylphenidate (ADHD) to pipeline; lead product AVERSA Fentanyl has $80-200M potential US sales.

• January 10, 2022, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Nutriband signs feasibility agreement with Kindeva to develop abuse deterrent fentanyl patch AVERSA

  Agreement combines Nutriband's AVERSA abuse deterrent technology with Kindeva's FDA-approved fentanyl patch.

• October 12, 2021, 7:59 PM ET other material materiality 0.65 positive item 1.01item 9.01

  Nutriband signs exclusive manufacturing deal for COVID-19 antibody monitoring patch

  Exclusive manufacturing agreement via subsidiary Active Intelligence, LLC with Diomics for Diocheck™ patch.

• October 8, 2021, 7:59 PM ET other material materiality 0.75 positive item 3.02item 8.01item 5.02 ◈ executive_change

  Nutriband completes IPO on Nasdaq, nets $5.8M; elects Serguei Melnik as President

  IPO of 1,056,000 units at $6.25/unit, each unit = 1 share + 1 warrant; underwriters' option exercised for 158,400 warrants.

• October 1, 2021, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Nutriband receives USPTO Notice of Allowance for abuse-deterrent transdermal patent

  USPTO allowed patent application 16/707,547 on Sept 27, 2021.

Executive changes

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event other_material

23 positive 1 negative 21 neutral

source · NTRB on sec.gov